Lysosomal & Rare Disorders Research & Treatment Center

Lysosomal Storage Diseases: Central Symptoms and Comorbidities

February 1, 2022 – February 1 2023

NO LONGER AVAILABLE FOR CREDIT

Estimated time to complete: 1.0 hours

Continuing Education Information

This continuing education activity is provided through collaboration between Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), CheckRare, and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurses, nurse practitioners, and genetic counselors. A statement of participation is available for other attendees.

Activity Description

This CME activity highlights how symptoms and comorbidities involving the central nervous system have a key role in how physicians manage patients with lysosomal storage disorders. Key medical problems discussed include cognitive deterioration, behavioral disorders, ophthalmologic problems, neuromuscular deterioration, Parkinson’s disease, depression, and seizures. Newer therapies that allow treatment to cross the blood brain border are also discussed.

Faculty

Dr. Ozlem Goker-Alpan
Founder and President
Lysosomal & Rare Disorders Research & Treatment Center (LDRTC)

Swati Sathe, MD
Medical Director, CHDI Management; Associate Professor (Voluntary), Rutgers NJMS

Learning Objectives

At the end of this activity, participants should be able to:

• Describe the spectrum of neurological involvement in LSDs
• Describe the pathophysiology of CNS involvement in LSDs
• Review current therapies and how they help neurological involvement in LSDs
• Describe how newer treatment may impact neurological symptoms in certain LSDs

Disclosures

AffinityCE staff, LDRTC staff, planning, and review committees have no financial interests to disclose and do not recommend the use of products outside of the FDA approved labelling.

Dr. Swati Sathe has no relevant financial interests to disclose.

Faculty disclosures

Dr. Ozlem Goker-Alpan
Speaker: BioEvents
Consultant: Cheisi, Sanofi Genzyme, Takeda, Amicus Therapeutics, Prevail Therapeutics, Freeline
Grant Recipient: Chiesi, Takeda, Sanofi Genzyme, Amicus Therapeutics, Avrobio, Centogene, Idorsia, 4DMT, Sangamo, Protalix
Principal Investigator: Cheisi, Takeda, Sanofi Genzyme, Amicus Therapeutics, Avrobio, Idorsia, 4DMT, Sangamo, Protalix

Mitigation of Relevant Financial Relationships

All relevant financial relationships have been mitigated prior to the launch of this program to participants. Conflict of interest for Dr. Goker-Alpan was resolved through peer review of content by a non-conflicted reviewer.

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring activity for a maximum of 1 hour of AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring activity for a maximum of 1 hour of AMA PRA Category 1 Credit™. Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Continuing Nursing Education is provided for this program through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC). This activity provides a maximum of 1 hour of continuing nursing education credit.

Nurse Practitioners

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring activity for a maximum of 1 hour of AMA PRA Category 1 Credit™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.

Genetic Counselors

Category 2 CEU

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this enduring activity for a maximum of 1 hour of AMA PRA Category 1 Credit™. This activity meets Category 2 CEUs requirements of the National Society of Genetic Counselors (NCGC).

Other Professionals

All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.

Commercial Support

Educational Support for this activity was provided by Takeda, Chiesi, Ultragenyx Pharmaceutical, and Spark Therapeutics.

Participation Costs

There is no cost to participate in these CE sessions.

CME Inquiries

For all CME policy-related inquiries, please contact us at ce@affinityced.com.
Send customer support requests to cds_support+ldrtc@affinityced.com.